ARTICLE | Company News

Baxter sales and marketing update

November 3, 2014 8:00 AM UTC

Baxter launched HyQvia Ig infusion 10% in the U.S. to treat adults with primary immunodeficiency. Baxter said HyQvia gives patients the option of monthly self-administration or administration by a professional, while other marketed subcutaneous Ig products require weekly or bi-weekly treatment with multiple infusion sites per treatment. The product is marketed in a range of 26.25-315 mL packages of 160 U/mL. The wholesale acquisition cost (WAC) is $400 for the 26.25 mL package and $4,800 for the 315 mL package. Baxter said it is working with major insurers to gain coverage. ...